August 11, 2026

To, **BSE Limited**, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	To, Listing Department, **National Stock Exchange of India Ltd**., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol: CAMLINFINE || Series: EQ

Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ("SEBI Listing Regulations") (read with Schedule III).

Dear Sir/Madam,

This has reference to our intimation dated August 4, 2026.

This is to inform you that the Board of Directors, at its meeting held today i.e. on Tuesday, August 11, 2026, inter alia, approved the Un-audited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026, as recommended by the Audit Committee. A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1. The said Results shall be published in newspapers as per the SEBI Listing Regulations.

The same are also being uploaded on the Company's Website at (https://www.camlinfs.com/).

The Board meeting commenced at 02:00 p.m. (IST) and concluded at 03:35 p.m. (IST).

This is for your information and record please.

Encl.: a/a.
Thanking You,
For Camlin Fine Sciences Limited

RAHUL SAWALE
Digitally signed by RAHUL SAWALE
Date: 2026.08.11 15:56:04 +05'30'

Rahul Sawale
Company Secretary
& VP - Legal

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

ANNEXURE - 1

CAMLIN FINE SCIENCES LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rs.in Million, except per share data)

		PARTICULARS	STANDALONE				CONSOLIDATED			
			QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
			30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
			(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1		Revenue from operations	2,224.86	1,835.17	1,914.38	8,379.18	5,198.79	4,248.11	4,077.21	17,233.08
2		Other income	14.02	153.02	36.89	349.51	13.40	239.12	66.27	287.92
3		**Total Income**	2,238.88	1,988.19	1,951.27	8,728.69	5,212.19	4,487.23	4,143.48	17,521.00
4		**Expenses**								
		Cost of materials consumed	1,455.98	776.79	990.61	4,018.22	3,123.48	1,207.29	2,258.55	8,232.70
		Purchase of stock in trade	14.88	20.44	4.71	36.91	58.20	181.61	198.94	886.01
		Changes in inventories of finished goods/WIP/stock in trade	(141.35)	168.01	29.50	404.05	(124.85)	798.98	(200.63)	105.75
		Employee benefits expense	202.78	180.75	186.21	759.80	734.29	659.31	567.42	2,439.01
		Finance costs	133.82	220.51	113.44	669.87	140.05	229.80	148.56	729.40
		Depreciation and amortisation expense	135.12	132.85	134.03	536.77	191.56	208.15	161.34	709.19
		Other expenses	624.37	629.09	656.54	2,681.31	1,314.92	1,189.07	1,050.00	4,500.82
		Total Expenses	2,425.60	2,128.44	2,115.04	9,106.92	5,437.65	4,474.20	4,184.18	17,602.88
5		**Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)**	(186.72)	(140.25)	(163.77)	(378.23)	(225.46)	13.03	(40.70)	(81.88)
6		**Exceptional items (Refer Note 7)**	-	26.11	-	162.70	111.10	79.49	-	254.60
7		**Profit / (Loss) before share of profit / (loss) of associate (5-6)**	(186.72)	(166.36)	(163.77)	(540.92)	(336.56)	(66.46)	(40.70)	(336.48)
8		**Share of profit / (loss) of associate**	-	-	-	-	13.97	13.83	8.91	16.62
9		**Profit / (Loss) before tax from continuing operations (7-8)**	(186.72)	(166.36)	(163.77)	(540.92)	(322.59)	(52.63)	(31.79)	(319.86)
10		**Tax Expenses**								
		- Current tax	-	-	-	-	38.57	19.21	59.76	179.21
		- Deferred tax	(63.60)	(109.87)	(56.96)	(211.26)	(43.20)	(81.58)	(60.02)	(183.76)
		Total Tax Expenses	(63.60)	(109.87)	(56.96)	(211.26)	(4.63)	(62.37)	(0.26)	(4.55)
11		**Profit / (Loss) from continuing operations for the period (9-10)**	(123.12)	(56.49)	(106.81)	(329.66)	(317.96)	9.74	(31.53)	(315.31)
12		**Discontinued operations**								
		Profit / (Loss) from discontinued operation before tax	-	-		-	(18.26)	854.71	(75.28)	552.42
		Tax expense of discontinued operations	-	-		-	-	1.68	-	1.68
		Profit / (Loss) from discontinued operations	-	-	-	-	(18.26)	853.03	(75.28)	550.74
13		**Profit / (Loss) for the period (11+12)**	(123.12)	(56.49)	(106.81)	(329.66)	(336.22)	862.77	(106.81)	235.43
14		**Other comprehensive income**								
A		Items that will not be reclassified to profit or loss								
	(i)	Remeasurements of defined benefit plans	(0.70)	6.53	1.56	(1.61)	(0.70)	6.91	1.56	(1.24)
	(ii)	Income tax relating to Items that will not be reclassified to profit or loss	0.24	(2.28)	(0.54)	0.56	0.24	(2.28)	(0.54)	0.56
B		Items that will be reclassified to profit or loss								
	(i)	Exchange differences on translating the financial statements of foreign operations					135.76	(109.37)	117.04	80.96
	(ii)	The effective portion of gain or loss on hedging instruments in a cash flow hedge	57.33	(21.79)	1.90	(70.57)	57.33	(21.79)	1.90	(70.57)
	(iii)	Income tax relating to Items that will be reclassified to profit or loss	(20.03)	7.61	(0.66)	24.66	(20.03)	7.61	(0.66)	24.66
		Other comprehensive income	36.84	(9.93)	2.25	(46.96)	172.60	(118.92)	119.29	34.37
15		Total comprehensive income for the period (13+14)	(86.28)	(66.42)	(104.56)	(376.62)	(163.62)	743.85	12.48	269.80

KALYANIWALLA & MISTRY LLP

CAMLIN FINE SCIENCES LIMITED MUMBAI

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361
+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CFS® Camlin Fine Sciences

		PARTICULARS	STANDALONE				CONSOLIDATED			
			QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
			30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
			(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
16		**Profit / (Loss) attributable to:**								
	(i)	Owners of the Company					**(317.06)**	882.02	(99.61)	276.27
	(ii)	Non-controlling interests					**(19.16)**	(19.25)	(7.20)	(40.84)
		Profit attributable to owners arises from:								
		Continuing operations					**(309.02)**	67.40	(29.57)	(300.81)
		Discontinued operations					**(8.04)**	814.62	(70.04)	577.08
17		**Other comprehensive income attributable to:**								
	(i)	Owners of the Company					**177.48**	(96.17)	119.06	71.11
	(ii)	Non-controlling interests					**(4.88)**	(22.75)	0.22	(36.74)
18		**Total comprehensive income attributable to:**								
	(i)	Owners of the Company					**(139.58)**	785.85	19.45	347.38
	(ii)	Non-controlling interests					**(24.04)**	(41.99)	(6.98)	(77.58)
		Total comprehensive income attributable to owners arises from:								
		Continuing operations					**(131.54)**	(28.77)	89.49	(229.70)
		Discontinued operations					**(8.04)**	814.62	(70.04)	577.08
19		Paid-up Equity Share Capital (Face Value Rs.1/- per share)	**192.10**	192.09	187.92	192.09	**192.10**	192.09	187.92	192.09
20		Other Equity				9,096.16				10,216.71
		Earnings per Share (EPS) for profit from continuing operation (of Re 1/- each) (not annualised)								
		Basic (Rs.)					**(1.60)**	0.35	(0.16)	(1.59)
		Diluted (Rs.)					**(1.60)**	0.35	(0.16)	(1.59)
		Earnings per Share (EPS) for profit from discontinued operation (of Re 1/-each) (not annualised)								
		Basic (Rs.)					**(0.05)**	4.24	(0.37)	3.05
		Diluted (Rs.)					**(0.05)**	4.19	(0.37)	3.01
21		Earnings per Share (EPS) for profit from continuing and discontinued operation (of Re 1/-each) (not annualised)								
		Basic (Rs.)	**(0.64)**	(0.29)	(0.57)	(1.74)	**(1.65)**	4.59	(0.53)	1.46
		Diluted (Rs.)	**(0.64)**	(0.29)	(0.57)	(1.74)	**(1.65)**	4.54	(0.53)	1.44

Notes to Standalone and Consolidated Unaudited Financial Results:

1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 11, 2026. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.

2 The figures for the quarter ended March 31, 2026 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2026 and the published year to date figures up to the end of the third quarter of the relevant financial year which had only been reviewed and not subjected to audit.

3 Other income / Other expense above relating to continuing operations includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
	30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	-	133.58	6.12	239.92	-	186.28	61.44	189.51
Exchange loss	9.20	-	-	-	83.69	-	-	-
Total Exchange Gain / (Loss)	(9.20)	133.58	6.12	239.92	(83.69)	186.28	61.44	189.51

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

KALYANIWALLA & MISTRY LLP

CAMLIN FINE SCIENCES LIMITED MUMBAI

Camlin Fine Sciences

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361
+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

4 Finance costs of continuing operation include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
	30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	1.83	-	1.03	-	22.73	-	-	-
Exchange loss	-	86.81	-	174.27	-	41.81	9.25	82.39
Total Exchange Gain / (Loss)	**1.83**	**(86.81)**	**1.03**	**(174.27)**	**22.73**	(41.81)	(9.25)	(82.39)

5 During the current quarter, the Company has neither issued nor allotted employee stock options under any of the Employees Stock Option Plans (ESOP) . 80,000 employee stock options have lapsed under ESOP-2021 which have been added back to the option pool and are eligible for re-issue.

6 Pursuant to the acquisition of Vinpai S.A. ('Vinpai') in FY 2026, the Company held 3,823,316 equity shares (excluding 26,736 treasury shares) representing 83.82% of Vinpai's outstanding share capital as on March 31, 2026. On June 23, 2026 , an open offer for the minority shareholders was launched at a price of Euro 3.60 per equity share. The offer was closed on July 6, 2026 and 501,842 equity shares amounting to Rs. 194.63 Million were transferred. Consequently, on July 6, The Company holds 4,351,894 equity shares representing 95.41% of Vinpai's outstanding share capital.

7 Exceptional Items includes Rs. 108.8 Million being the shortfall arising from the settlement of Insurance claim with respect to the fire incident that occurred on February 7, 2026 at one of the blending unit of CFS Do Brasil Industria, Comercio, Importacao e exportacao de Aditivos Alimenticios LTDA, a wholly owned subsidiary.

8 Loss from 'Discontinued Operations'

(a) As reported in the previous quarter the liquidation process of CFS Europe SpA, an erstwhile wholly owned subsidiary had commenced on March 17, 2026 and is still in progress. Consequent to the liquidation process and the consequential loss of control, the assets & liabilities of the subsidiary had been derecognized effective March 17, 2026 and the operations thereof had been classified as discontinued operations. During the quarter, the legal expenses of Rs. 2.50 Million incurred on the liquidation process have been included under the line item "Loss from "Discontinued Operations".

(b) It also include expenditure of Rs. 15.76 Million relating to the discontinued operations of subsidiary, CFS Wanglong Flavours (Ningbo) Co. Ltd.

9 With respect to the fire incident at Diphenol manufacturing unit at Dahej unit on May 23, 2026 , management is of the views that the loss of machinery, inventories and related expenses amounting to Rs. 67.03 Million is entirely covered by the insurance claim. Accordingly, the Company does not expect any residual loss arising on account of the incident.

10 As per the requirements of Ind AS-108 on "Operating Segment", Consolidated segment wise information has been provided in Annexure -1.

Place: Mumbai
Date: Aug 11, 2026

For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

CAMLIN FINE SCIENCES LIMITED MUMBAI

KALYANIWALLA & MISTRY LLP

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361
+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CFS Camlin Fine Sciences

CAMLIN FINE SCIENCES LIMITED
UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2026

(Rs. in Million)

	QUARTER ENDED			YEAR ENDED
PARTICULARS	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Segment Revenue				
Specialty Ingredients	4,013.17	3,389.89	2,936.08	13,116.23
Aroma	774.07	463.73	566.88	2,390.86
Performance Chemicals & Others	1,748.90	1,378.17	1,511.64	5,814.88
Gross Segment Revenue	**6,536.14**	**5,231.79**	**5,014.60**	**21,321.97**
Less: Inter Segment Revenue	1,337.35	983.68	937.39	4,088.89
Revenue from operations	**5,198.79**	**4,248.11**	**4,077.21**	**17,233.08**
Segment Results				
Specialty Ingredients	254.66	263.33	299.87	1,276.27
Aroma	(33.81)	(87.98)	(20.42)	(240.23)
Performance Chemicals & Others	(44.41)	36.51	(76.52)	32.75
Segment results before exceptional items	**176.44**	**211.86**	**202.93**	**1,068.79**
Less:				
Exceptional Items				
Specialty Ingredients	108.80	76.34	-	76.34
Aroma	-	-	-	-
Performance Chemicals & Others	-	-	-	-
Segment results after Exceptional Items	**67.64**	**135.52**	**202.93**	**992.45**
Less / (Add):				
(i) Finance costs	140.05	229.80	148.56	729.40
(ii) Depreciation & Amortisation	191.56	208.15	161.34	709.19
(iii) Other income	(13.40)	(239.12)	(66.27)	(287.92)
(iv) Foreign exchange loss	83.69	-	-	-
(v) Exceptional items (unallocated)	2.30	3.16	-	178.26
(vi) Share of profit / (loss) of associate	(13.97)	(13.83)	(8.91)	(16.62)
Loss before tax	**(322.59)**	**(52.63)**	**(31.79)**	**(319.86)**

	AS AT			
PARTICULARS	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Segment Assets				
Specialty Ingredients	12,034.58	11,487.74	7,782.69	11,487.74
Aroma	3,863.87	3,980.19	3,732.41	3,980.19
Performance Chemicals & Others	6,142.10	6,493.61	6,725.42	6,493.61
Unallocated	1,258.95	1,277.55	1,097.01	1,277.55
Total	**23,299.50**	**23,239.09**	**19,337.53**	**23,239.09**
Segment Liabilities				
Specialty Ingredients	7,362.00	6,886.61	4,418.37	6,886.61
Aroma	2,262.48	2,431.04	2,351.60	2,431.04
Performance Chemicals & Others	3,708.61	3,800.73	3,327.52	3,800.73
Unallocated	114.96	112.59	59.34	112.59
Total	**13,448.05**	**13,230.97**	**10,156.83**	**13,230.97**

Notes:

The Managing Directors review and evaluate the Group's operating performance to make decisions about resources to be allocated to various businesses and have been identified as Chief Operating Decision Makers (CODM).

Hitherto, the CODM used to review the operating performance of the Group with respect to a single segment namely, Speciality Chemical Business. With the nature and growth of the overall business, the changing economic environment and risk and reward profile of different businesses, the CODM, with effect from the current quarter, have determined that the Group should report the performance under three business reporting segments to provide a more meaningful analysis of the Group's financial performance. The business of each segment comprises of :

1. Specialty Ingredients · This is the main business area of the Group's operation and includes marketing of conventional antioxidant chemicals, and manufacturing and marketing of blends, emulsifiers, functional ingredients, starches, additives, etc. catering to industries engaged in Food, Animal Nutrition & Feed, Pet Food, Bio diesels, Oil & Fat, Dairy, Bakery, Confectionery, Meat, etc. All these products include inorganic, natural as well as clean label.

2. Aroma : This segment of the Group's operation includes manufacturing and marketing of aromatic products such as Methyl Vanillin, Ethyl Vanillin and related derivatives.

3. Performance Chemicals & Others: This segment will include the manufacturing and marketing of chemical such as Diphenols, Phenolic Compounds, Performance & Industrial chemicals and other downstream & derivatives. This segment will also include other minor residuary businesses.

Accordingly, segment information is presented in respect of the above identified business segments, wherein the performance is evaluated based on operational EBITDA (without foreign exchange gain / loss).

All inter-segment transactions are conducted on normal commercial terms not more favourable than those generally available to external parties and in line with the arm's length principle.

Comparative figures for previous financial periods have been recast to reflect the changes in the reporting segments and to ensure comparability with the segment information presented in the current quarter.

KALYANIWALLA & MISTRY LLP

CAMLIN FINE SCIENCES LIMITED MUMBAI

KALYANIWALLA
& MISTRY LLP
CHARTERED ACCOUNTANTS

REVIEW REPORT
To The Board of Directors
Camlin Fine Sciences Limited

1) We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Camlin Fine Sciences Limited** ("the Company") for the quarter ended June 30, 2026, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), duly initialled by us for identification. This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on August 11, 2026, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

4) **Other Matter**

   Attention is drawn to the fact that the figures for the quarter ended March 31, 2026, as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had been reviewed and were not subjected to audit.

   Our conclusion on the Statement is not modified in respect of the above matter.

For **Kalyaniwalla & Mistry LLP**
Chartered Accountants
Firm Registration No.: 104607W/W100166

AKulkarni

Anil A. Kulkarni
Partner
Membership No.: 047576
UDIN: 26047576JRURUS9528
August 11, 2026, Pune

KALYANIWALLA & MISTRY LLP

REVIEW REPORT
To The Board of Directors
Camlin Fine Sciences Limited

1) We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Camlin Fine Sciences Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit / (loss) after tax and total comprehensive income of an associate of a step down subsidiary (refer paragraph 3 below) for the quarter ended June 30, 2026 together with the notes thereon ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations"), duly initialled by us for identification. This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by Parent's Board of Directors, at their respective meetings held on August 11, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

3) The Statement includes the results of the following subsidiaries / step down subsidiaries / associate:

Sr. No.	Name of the Entity	Relationship
Incorporated In India		
i.	Chemolutions Chemicals Ltd.	Subsidiary
ii.	AlgalR Nutra Pharms Private Limited	Subsidiary
Incorporated Outside India		
iii.	CFS North America LLC	Wholly owned subsidiary
iv.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
v.	Solentus North America Inc (Struck off w.e.f. May 12, 2026)	Wholly owned subsidiary

KALYANIWALLA & MISTRY LLP

Sr. No.	Name of the Entity	Relationship
vi.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
vii.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
viii.	Nuvel, S.A.C.	Step down subsidiary
ix.	Britec, S.A.	Step down subsidiary
x.	Inovel, S.A.S	Step down subsidiary
xi.	Grinel, S.R.L	Step down subsidiary
xii.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xiii.	CFS Argentina S.A.	Step down subsidiary
xiv.	CFS Chile De SPA	Step down subsidiary
xv.	CFS PP (M) SDN. BHD	Subsidiary
xvi.	Vitafor Invest NV, Belgium	Step down subsidiary
xvii.	Vitafor NV,	Step down subsidiary
xviii.	Addi-Tech NV	Step down subsidiary
xix.	Vitafor China Ltd.	Step down subsidiary
xx.	Vial SARL	Associate of a step-down subsidiary
xxi.	Vinpai S. A. (w.e.f. November 30, 2025)	Subsidiary
xxii.	Based Algae & Plants, France (w.e.f. November 30, 2025)	Step down subsidiary

4) Based on our review conducted and procedures performed as stated in paragraph 2 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 5(A) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5) Other Matters:

A. We did not review the interim financial results of 13 subsidiaries incorporated outside India and 2 subsidiaries in India included in the Statement, whose interim financial results reflect Group's share of total revenues (before consolidation adjustments) of Rs. 3,707.93 million, Group's share of total net loss after tax (before consolidation adjustments) of Rs. 182.19 million and total comprehensive income (before consolidation adjustments) loss of Rs. 96.30 million for the quarter ended June 30, 2026.

These interim financial results of the subsidiaries as mentioned in this paragraph have been reviewed by other auditors whose reports have been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 2 above.

In respect of the subsidiaries located outside India, the interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed the conversion adjustments made by the Parent's Management.

KALYANIWALLA & MISTRY LLP

B. The Statement includes interim financial results of 6 subsidiaries incorporated outside India which have not been reviewed, whose interim financial results reflect Group's share of total revenues (before consolidation adjustments) of Rs. 22.82 million, Group's share of total net loss after tax (before consolidation adjustments) of Rs. 48.87 million and total comprehensive income (before consolidation adjustments) loss of Rs. 28.81 million for the quarter ended June 30, 2026.

The Statement also includes the Group's share of net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. 13.97 million for the quarter ended June 30, 2026 as considered in the consolidated unaudited financial results, in respect of an associate of a step-down subsidiary, located outside India, which have not been reviewed.

These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate of a step-down subsidiary, is based solely on such interim financial results certified by the Management. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

C. Attention is drawn to the fact that the figures for the quarter ended March 31, 2026, as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had been reviewed and not subjected to an audit.

Our conclusion on the Statement is not modified in respect of the above matters.

For **Kalyaniwalla & Mistry LLP**
Chartered Accountants
Firm Registration No.: 104607W/W100166

AKulkarni

Anil A. Kulkarni
Partner
Membership No.: 047576
UDIN: 26047576TCFMJA3625
August 11, 2026, Pune

KALYANIWALLA & MISTRY LLP

Camlin Fine Sciences

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2026									
		(Rs.in Million, except per share data)							
No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
		30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	2,224.86	1,835.17	1,914.38	8,379.18	5,198.79	4,248.11	4,077.21	17,233.08
2	Net Profit / (Loss) for the period from continuing operations (before tax and exceptional items)	(186.72)	(140.25)	(163.77)	(378.23)	(211.49)	26.86	(31.79)	(65.26)
3	Net Profit / (Loss) for the period before tax from continuing operations (after exceptional items)	(186.72)	(166.36)	(163.77)	(540.92)	(322.59)	(52.63)	(31.79)	(319.86)
4	Total Net Profit / (Loss) for the period after tax (after exceptional items)	(123.12)	(56.49)	(106.81)	(329.66)	(336.22)	862.77	(106.81)	235.43
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)					(317.06)	882.02	(99.61)	276.27
6	Total Comprehensive Income for the period	(86.28)	(66.42)	(104.56)	(376.62)	(163.62)	743.85	12.48	269.80
7	Equity Share Capital	192.10	192.09	187.92	192.09	192.10	192.09	187.92	192.09
8	Other Equity				9,096.16				10,216.71
9	Earnings per share (of Re 1/-each) (not annualised)								
	-Basic Rs.	(0.64)	(0.29)	(0.57)	(1.74)	(1.65)	4.59	(0.53)	1.46
	-Diluted Rs.	(0.64)	(0.29)	(0.57)	(1.74)	(1.65)	4.54	(0.53)	1.44

Note -The above information is an extract of the detailed format of unaudited results for the quarter ended June 30, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter June 30, 2026 are available on the Company's website at www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

CAMLIN FINE SCIENCES LIMITED MUMBAI

Place: Mumbai
Date: Aug 11, 2026

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361
+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com